Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.58 |
| ▸ | MAOA | P21397 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CALML3 | P27482 | 1/20 | 0.54 |
| ▸ | SDHA | P31040 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80077 | 1.00 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL2948879 | 0.91 | MAOB (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL6111262 | 0.91 | MAOB (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL6613535 | 0.91 | MAOB (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL13174832 | 0.89 | MAOB (0.55) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL2480376 | 0.89 | MAOA (0.48) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL18059593 | 0.89 | MAOA (0.48) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5810297 | 0.88 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5412271 | 0.88 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL13271873 | 0.88 | MAOB (0.49) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-16 | — | — | US | disclosed |
| EP-0640077-B1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | UPJOHN CO (US) | 2002-06-26 | — | — | EP | disclosed |
| CN-1044236-C | Oxazolidinone antimicrobials containing substituted diazine moieties | PHARMACIA UPJOHN CO (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5700799-A | MICROBIOCIDES FOR TREATING HUMAN OR ANIMAL DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5547950-A | FOR TREATING DRUG RESISTANT STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | THE UPJOHN COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0640077-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023384-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | THE UPJOHN COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | HTRA1, PRSS1, PRNP | MAOB 2054/4885MAOA 2174/4885LMNA 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.